Dr. Tina Vilsboll |
That’s the conclusion of a new study that analyzed the data from 25 trials involving 6,411 patients conducted over the last seven years. The first GLP-1 drug to receive FDA approval was Byetta®, which is injected twice daily into the abdomen, thigh or shoulder an hour before breakfast and dinner. Victoza® is a long-acting GLP-1 agonist injected once daily. Bydureon® is a once-a-week injection formula of Byetta. (Published site)